High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Antithrombotic therapy.
- Who it may be relevant to
- Registry conditions: Acute Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Spain
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prescription of High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department. Retrospective Cohort Study
Overview
This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.
Interventions
- Other Antithrombotic therapy
Anticoagulant treatment prescribed at discharge from an acute care unit
Primary outcome measures
- Hemorragic event [Time frame: Day 90 from baseline]
Eligibility criteria
Inclusion criteria
- Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:
B01AA - Vitamin K antagonists: warfarin and acenocoumarol
B01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …
B01AE - Direct thrombin inhibitors: dabigatran
B01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban
Exclusion criteria
- Those who are not part of the CSAPG healthcare area.
- Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Spain · 1 center
- Hospital de Vilafranca — Vilafranca del Penedès
Identifiers
NCT: NCT07278648 · CSAPG-79